sorafenib has been researched along with Condition, Preneoplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H | 1 |
| Cohen, PR; Stewart, DJ; Williams, VL | 1 |
1 review(s) available for sorafenib and Condition, Preneoplastic
| Article | Year |
|---|---|
Sorafenib-induced premalignant and malignant skin lesions.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Niacinamide; Phenylurea Compounds; Precancerous Conditions; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
1 other study(ies) available for sorafenib and Condition, Preneoplastic
| Article | Year |
|---|---|
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib | 2014 |